+

WO1996009066A3 - Method of treatment of human immunodeficiency virus (hiv) infection - Google Patents

Method of treatment of human immunodeficiency virus (hiv) infection Download PDF

Info

Publication number
WO1996009066A3
WO1996009066A3 PCT/US1995/011943 US9511943W WO9609066A3 WO 1996009066 A3 WO1996009066 A3 WO 1996009066A3 US 9511943 W US9511943 W US 9511943W WO 9609066 A3 WO9609066 A3 WO 9609066A3
Authority
WO
WIPO (PCT)
Prior art keywords
infection
hiv
immunodeficiency virus
siv
treatment
Prior art date
Application number
PCT/US1995/011943
Other languages
French (fr)
Other versions
WO1996009066A2 (en
Inventor
Janice E Clements
Michael Murphey-Corb
M Christine Zink
Original Assignee
Univ Johns Hopkins Med
Univ Tulane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins Med, Univ Tulane filed Critical Univ Johns Hopkins Med
Priority to EP95933167A priority Critical patent/EP0784484A2/en
Priority to AU35930/95A priority patent/AU3593095A/en
Publication of WO1996009066A2 publication Critical patent/WO1996009066A2/en
Publication of WO1996009066A3 publication Critical patent/WO1996009066A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method of treating a host prophylactically or therapeutically for infection with human immunodeficiency virus (HIV) is described. A simian immunodeficiency virus (SIV)-macaque monkey model shows that infection with a non-pathogenic, macrophage-tropic, recombinant SIV provides systemic immunity to the host by stimulation of production of neutralizing antibodies. Tests provided show that the neutralizing antibodies produced are broadly reactive with several heterologous strains of SIV. Also provided are pharmaceutical compositions useful for treatment of a subject prior to or following infection with HIV.
PCT/US1995/011943 1994-09-23 1995-09-19 Method of treatment of human immunodeficiency virus (hiv) infection WO1996009066A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP95933167A EP0784484A2 (en) 1994-09-23 1995-09-19 Method of treatment of human immunodeficiency virus (hiv) infection
AU35930/95A AU3593095A (en) 1994-09-23 1995-09-19 Method of treatment of human immunodeficiency virus (hiv) infection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31142494A 1994-09-23 1994-09-23
US08/311,424 1994-09-23

Publications (2)

Publication Number Publication Date
WO1996009066A2 WO1996009066A2 (en) 1996-03-28
WO1996009066A3 true WO1996009066A3 (en) 1996-05-23

Family

ID=23206813

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/011943 WO1996009066A2 (en) 1994-09-23 1995-09-19 Method of treatment of human immunodeficiency virus (hiv) infection

Country Status (3)

Country Link
EP (1) EP0784484A2 (en)
AU (1) AU3593095A (en)
WO (1) WO1996009066A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
US7282364B2 (en) 2001-08-31 2007-10-16 Novartis Vaccines And Diagnostics, Inc. Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US7348177B2 (en) 1998-12-31 2008-03-25 Novartis Vaccines And Diagnostics, Inc. Expression of HIV polypeptides and production of virus-like particles

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2358385C (en) 1998-12-31 2013-08-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021806A1 (en) * 1993-03-19 1994-09-29 Medical Research Council Delivery system controlled through factors associated with hiv and cell

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021806A1 (en) * 1993-03-19 1994-09-29 Medical Research Council Delivery system controlled through factors associated with hiv and cell

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FERNANDO PLATA ET AL.: "AIDS virus-specific cytotoxic T lymphocytes in lung disorders", NATURE, vol. 328, pages 348 - 351 *
JANICE E. CLEMENTS ET AL.: "Cross-Protective Immune Responses Induced in Rhesus Macaques by Immunization with Attenuated Macrophage-Tropic Simian Immunodeficiency Virus", JOURNAL OF VIROLOGY, vol. 69, no. 5, pages 2737 - 2744 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7348177B2 (en) 1998-12-31 2008-03-25 Novartis Vaccines And Diagnostics, Inc. Expression of HIV polypeptides and production of virus-like particles
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
US9598469B2 (en) 2001-07-05 2017-03-21 Novartis Vaccines And Diagnostics, Inc. HIV-1 south african subtype C env proteins
US7282364B2 (en) 2001-08-31 2007-10-16 Novartis Vaccines And Diagnostics, Inc. Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof

Also Published As

Publication number Publication date
WO1996009066A2 (en) 1996-03-28
AU3593095A (en) 1996-04-09
EP0784484A2 (en) 1997-07-23

Similar Documents

Publication Publication Date Title
ATE122237T1 (en) HIV-1 NEUTRALIZING MONOCLONAL ANTIBODIES.
CA2082948A1 (en) Immunogenic peptides, antibodies and uses thereof relating to cd4 receptor binding
CA2363947A1 (en) Hiv peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv
GR3023717T3 (en) Process for recovering native domains of viral membrane proteins, their use, in particular as vaccine against hiv.
AU1347688A (en) Viral antigen, process for its production, and application in diagnosis and therapy (vaccine)
WO1996009066A3 (en) Method of treatment of human immunodeficiency virus (hiv) infection
AU1226288A (en) Processes for the preparation of medicinal compositions, compositions obtained by these processes and use thereof for the preparation of medicines against viral hepatitis b and acquired immunodeficiency syndrome
WO1990013281A3 (en) Method of suppressing hiv infection
WO1993001820A3 (en) Inhibition of non-cd4 mediated hiv infection
EP0315459A3 (en) Hiv incomplete particles and a method for production thereof
AP9600896A0 (en) Anti-HIV triple combination.
EP0385909A3 (en) A kit or composition for the prevention or treatment of HIV-1 infections
EP0345028A3 (en) Treatment of glaucoma using phosphodiesterase inhibitor
AU4832097A (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
EP0235904A3 (en) Treatment of allergy with thymopentin
IL139360A0 (en) Viral chimeras comprised of caev and hiv-1 genetic elements
WO2003089000A3 (en) Anti-hiv composition, production method thereof and medicament
AU3335689A (en) Recombinant gag precursor of hiv, product, process, and use as aids vaccine
WO2024130122A3 (en) Hiv immunogens and methods of using same
HUP0003511A2 (en) Hepatitis b virus polypeptides
PT85602A (en) Oxolabdanes a process for their preparation and their use as medicaments
AU627540B2 (en) Drug for the treatment or prevention by passive immunization, of the hiv-infection and process for preparation thereof
EP0218431A3 (en) Novel polypeptides, dnas that code for the same and method of preparing said polypeptides and dnas
CA2042534A1 (en) Treatment and/or a Method of Treating
EP0309898A3 (en) Method for the induction of a cytotoxic t cell response

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995933167

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1995933167

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995933167

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载